[Gastrointestinal cancer].

Abstract

Ten patients with refractory gastrointestinal cancer received nonmyeloablative allogeneic stem-cell transplantation(NST) from HLA-identical sibling. The conditioning regimen consisted of cyclophosphamide and fludarabine. None of the patients rejected the allograft. Five patients developed grade II-III acute GVHD and 5 patients developed extensive chronic GVHD. Three patients achieved remarkable serum tumor marker regressions after the steroids were discontinued, which were attributed to graft-versus-tumor (GVT) effects. One patient achieved a partial response, and three patients had stable disease. At a median follow up of 155.5 days (52-349), 2 patients are alive and 8 patients died for progressive disease. NST for refractory gastrointestinal cancer was feasible. Although GVT effects against gastrointestinal cancer were observed, the effects were limited for highly progressive disease.

• Authors: Yasushi Omuro, Tsuneo Sasaki
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 61 Issue 9 Pg. 1601-6 (Sep 2003) ISSN: 0047-1852 [Print] Japan
• PMID: 14515731 (Publication Type: English Abstract, Journal Article)

Chemical References

• Immunosuppressive Agents
• Cyclophosphamide
• Vidarabine
• fludarabine

Topics

• Adult
• Aged
• Cyclophosphamide (therapeutic use)
• Female
• Gastrointestinal Neoplasms (therapy)
• Graft vs Host Disease (etiology)
• Graft vs Tumor Effect
• Humans
• Immunosuppressive Agents (therapeutic use)
• Male
• Middle Aged
• Retrospective Studies
• Stem Cell Transplantation (adverse effects)
• Transplantation Chimera
• Transplantation Conditioning (adverse effects)
• Transplantation, Homologous
• Treatment Outcome
• Vidarabine (analogs & derivatives, therapeutic use)